Novavax's stock surged 12% in premarket trade Monday after the drug maker said it expects to initiate a Phase 1 clinical trial of its Ebola vaccine in December. The company said it had recently initiated a non-human primate study of its vaccine candidate, named EBOV GP. Novavax said EBOV GP, modified with its Matrix-M adjuvant, helped induce neutralizing antibody levels within ranges reported to protect against Ebola viruses in rodent and non-human primate models. The stock was up 0.2% so far this year through Friday, compared with a 6.3% gain in the S&P 500.
Copyright © 2014 MarketWatch, Inc.
Continue Reading Below